These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Regulating scientific research: intellectual property rights and the norms of science. Rai AK Northwest Univ Law Rev; 1999; 94(1):77-152. PubMed ID: 12784815 [No Abstract] [Full Text] [Related]
3. Ownership of knowledge--the role of patents in pharmaceutical R&D. Correa CM Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801 [TBL] [Abstract][Full Text] [Related]
4. Sitting up and taking notice. Nat Biotechnol; 2010 May; 28(5):381. PubMed ID: 20458284 [No Abstract] [Full Text] [Related]
5. Developing an intellectual property portfolio for the academic or not-for-profit institution. Bloomberg CA Nat Biotechnol; 2005 Jan; 23(1):119-21. PubMed ID: 15637626 [No Abstract] [Full Text] [Related]
6. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]
7. Industry and academia in transition. Kennedy D Science; 2003 Nov; 302(5649):1293. PubMed ID: 14631000 [No Abstract] [Full Text] [Related]
9. Testing time for gene patents. Nature; 2010 Apr; 464(7291):957. PubMed ID: 20393513 [No Abstract] [Full Text] [Related]
10. Property rights go East. Nature; 2005 Nov; 438(7067):420-1. PubMed ID: 16306959 [No Abstract] [Full Text] [Related]
11. The role of the private sector in biotechnology: research and development. Feisee L Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359 [No Abstract] [Full Text] [Related]
12. Transferring innovation. Kesan JP Fordham Law Rev; 2009 Apr; 77(5):2169-223. PubMed ID: 19431909 [No Abstract] [Full Text] [Related]
13. Actor-network theory: a tool to support ethical analysis of commercial genetic testing. Williams-Jones B; Graham JE New Genet Soc; 2003 Dec; 22(3):271-96. PubMed ID: 15115034 [TBL] [Abstract][Full Text] [Related]
15. Intellectual property and biotechnology: the U.S. internal experience--Part II. Brody B Kennedy Inst Ethics J; 2006 Jun; 16(2):105-28. PubMed ID: 17036443 [TBL] [Abstract][Full Text] [Related]
16. Bioterrorism and patent rights: "compulsory licensure" and the case of Cipro. Resnik DB; DeVille KA Am J Bioeth; 2002; 2(3):29-39. PubMed ID: 12230852 [No Abstract] [Full Text] [Related]
17. Patent law. New rules for German professors. Kilger C; Bartenbach K Science; 2002 Nov; 298(5596):1173-5. PubMed ID: 12424355 [No Abstract] [Full Text] [Related]
18. [Revocation of the BRCA1 patents by the European Office of Patents: a victory over a rights abuse]. Stoppa-Lyonnet D; Lenoir G Bull Cancer; 2005 Apr; 92(4):410-1. PubMed ID: 15888396 [No Abstract] [Full Text] [Related]
19. [Industry and pharmaceutical research in Italy. How to make up for lost time]. Mortari U Recenti Prog Med; 2006 Nov; 97(11):634-9. PubMed ID: 17252720 [TBL] [Abstract][Full Text] [Related]
20. Genetic diagnosis and intellectual property rights: a proposal to amend "the physician immunity statute". Lekovic GP Yale J Health Policy Law Ethics; 2004; 4(2):275-304. PubMed ID: 15536912 [No Abstract] [Full Text] [Related] [Next] [New Search]